Baseline characteristics
| Characteristics | Value |
|---|---|
| Total number of participants | 106 |
| Number of men (%) | 94 (89) |
| Age (years), mean (SD) | 61 (11) |
| Gout: | |
| Duration (years), mean (SD) | 14 (13) |
| Acute attacks ever (%) | 100 |
| Chronic joint symptoms (%) | 46 |
| Tophi: | |
| Clinically evident tophi at baseline (%) | 17 (16) |
| Renal function: | |
| Baseline eGFR (ml/min/1.73 m2), mean (SD) | 65 (12) |
| Baseline creatinine (µmol/l), mean (SD) | 102 (20) |
| Attacks: | |
| Number of attacks in year before study, mean (SD) | 4 (4) |
| SUA: | |
| Baseline SUA (µmol/l), mean (SD) | 456 (98) |
| SUA (µmol/l), median (range) | 509 (160-716) |
| Number (%) with baseline SUA <360 µmol/l | 14 (13) |
| Number (%) with baseline SUA <300 µmol/l | 5 (5) |
| ULT: | |
| Number receiving ULT at baseline (%) | 28 (26) |
| Allopurinol | 27 |
| Sulphinpyrazone | 1 |
| Duration ULT (years), mean (SD) | 5 (7) |
| Comorbidities number (%): | |
| Hypertension | 40 (38) |
| Renal impairment (eGFR <60 ml/min/1.73 m2) | 32 (30) |
| Hyperlipidaemia | 21 (20) |
| Ischaemic heart disease | 12 (11) |
| Diabetes | 11 (10) |
eGFR, estimated glomerular filtration rate; SUA, serum uric acid; ULT, urate-lowering therapy.